An Economic Evaluation of Donepezil in Mild to Moderate Alzheimer’s Disease: Results of a 1-Year, Double-Blind, Randomized TrialWimo A. · Winblad B. · Engedal K. · Soininen H. · Verhey F. · Waldemar G. · Wetterholm A.-L. · Mastey V. · Haglund A. · Zhang R. · Miceli R. · Chin W. · Subbiah P.
aDepartment of Family Medicine, Umeå University, Umeå, and bKarolinska Institutet, Huddinge, Sweden; cDepartment of Geriatric Medicine, Ullevaal University Hospital, Oslo, Norway; dDepartment of Neurology, University and University Hospital of Kuopio, Finland; eDepartment of Psychiatry, University Hospital of Maastricht, Institute of Brain and Behaviour, Maastricht, The Netherlands; fThe Neuroscience Center, Department of Neurology, Rigshospitalet, University Hospital, Copenhagen, Denmark; gPfizer AB, Taby, Sweden; hPfizer Inc., New York, N.Y., USA; iAxia Research, Toronto, Canada
The costs and consequences of donepezil versus placebo treatment in patients with mild to moderate Alzheimer’s disease (AD) were evaluated as part of a 1-year prospective, double-blind, randomized, multinational clinical trial. Patients received either donepezil (n = 142; 5 mg/day for 28 days followed by 10 mg/day according to the clinician’s judgement) or placebo (n = 144). Unit costs were assessed in 1999 Swedish kronas (SEK) and converted to US dollars (USD). Donepezil-treated patients gained functional benefits relative to placebo on the Progressive Deterioration Scale (p = 0.042) and Instrumental Activities of Daily Living scale (p = 0.025) at week 52. Caregivers of donepezil-treated patients spent an average of 400 h less annually providing care than caregivers of placebo-treated patients. Mean annual healthcare costs were SEK 137,752 (USD 16,438) per patient for the donepezil group and SEK 135,314 (USD 16,147) in the placebo group. With the average annual cost of donepezil at SEK 10,723 (USD 1,280) per patient, the SEK 2,438 (USD 291) cost difference represented a 77% cost offset. When caregiver time and healthcare costs were included, mean annual costs were SEK 209,244 (USD 24,969) per patient in the donepezil group and SEK 218,434 (USD 26,066) in the placebo group, a total saving associated with donepezil treatment of SEK 9,190 (USD 1,097) per patient [95% CI of SEK –43,959 (USD –5,246), SEK 25,581 (USD 3,053); p = 0.6]. The positive effects on the efficacy outcome measures combined with no additional costs from a societal perspective indicate that donepezil is a cost-effective treatment, representing an improved strategy for the management of patients with AD.
Dr. Anders Wimo
HC Bergsjo, Box 16
SE–820 70 Bergsjo (Sweden)
Tel. +46 8 652 17261, Fax +46 8 652 71261
Accepted: August 19, 2002
Number of Figures : 2, Number of Tables : 2, Number of References : 42
Dementia and Geriatric Cognitive Disorders
Vol. 15, No. 1, Year 2003 (Cover Date: Released December 2002)
Journal Editor: V. Chan-Palay, New York, N.Y.
ISSN: 1420–8008 (print), 1421–9824 (Online)
For additional information: http://www.karger.com/journals/dem